XJPX
4882
Market cap17mUSD
Oct 09, Last price
153.00JPY
1D
2.00%
1Q
-3.16%
IPO
-81.18%
Name
Perseus Proteomics Inc
Chart & performance
P/E
—
P/S
20.81
EPS
—
Div yield, %
—
Shrs. gr., 5y
4.99%
Rev. gr., 5y
14.80%
Revenues
136m
+12.57%
Net income
-718m
L-20.63%
CFO
-653m
L-9.19%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Based in Tokyo, Japan, Perseus Proteomics Inc. operates as a biotechnology venture specializing in the development of antibody-based therapeutics for various ailments, including cancer. Its core operations encompass pioneering antibody discovery, alongside providing extensive research support services. These services include hybridoma antibody sequencing, the production of antibody proteins, and undertaking contract antibody research projects. Furthermore, Perseus Proteomics supplies its own antibody products to the market. The company boasts a robust development pipeline featuring several promising candidates: PPMX-T001, an antibody targeting hepatocarcinoma; PPMX-T002, an oncology therapeutic; PPMX-T003, designed for the treatment of adult T-cell leukemia/lymphoma; and PPMX-T004, an innovative antibody-drug conjugate. Established in 2001, the firm maintains its headquarters in the Japanese capital.
Key people
Shinji Hagiwara
Executive Officer, Director of Research and Development, Director of Business Development, Director · since 2023
Tadashi Matsuura
Executive Officer · since 2023
Shinichi Suzukawa
Executive Officer, Director of Administration, Director · since 2020
Yasuo Ichinose
Executive Officer, Director of Administration, Director · since 2019
Takuya Yokokawa
President, Chief Executive Officer, Executive Officer, Representative Director · since 2019
Independent Director · since 2021
Tadashi Horiuchi
Independent Director · since 2020
Kinichiro Kominami
Independent Director · since 2018
Tatsuya Nagase
Independent Director · since 2022
Takashi Ohno
Independent Director · since 2021
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2026‑03 | 2025‑03 | 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||